|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Hodgkin Disease
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Adult Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Choriocarcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Further, treatment of the choriocarcinoma cell line, JEG-3, with recombinant human interferon (IFN)-gamma resulted in a dose-dependent increase in the abundance of the message for B7-H1, suggesting that IFN-gamma could regulate expression of B7-H1 by the trophoblast.
|
11978065 |
2002 |
|
HIV Infections
|
0.070 |
AlteredExpression
|
group |
LHGDN |
Aberrant antigen presentation by antigen-presenting cells (APCs) that exhibit increased B7-H1 expression and IL-10 production in HIV infection could be responsible for T-lymphocyte unresponsiveness and loss of protective immunity.
|
12468426 |
2003 |
|
HIV Infections
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Aberrant antigen presentation by antigen-presenting cells (APCs) that exhibit increased B7-H1 expression and IL-10 production in HIV infection could be responsible for T-lymphocyte unresponsiveness and loss of protective immunity.
|
12468426 |
2003 |
|
AIDS (Disease)
|
0.010 |
Biomarker
|
disease |
BEFREE |
B7-H1 is a surrogate marker potentially involved in AIDS disease progression.
|
12468426 |
2003 |
|
Myositis
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
Further, we investigated 23 muscle biopsy specimens from patients with polymyositis (PM), inclusion body myositis (IBM), dermatomyositis (DM), and nonmyopathic controls for B7-H1 expression by immunohistochemistry: B7-H1 was expressed in PM, IBM, and DM specimens but not in noninflammatory and nonmyopathic controls.
|
12923066 |
2003 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
|
14559843 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1.
|
14559843 |
2003 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
B7-H1 expression may thus significantly influence the outcome of T-cell tumor cell interactions and represents a novel mechanism by which glioma cells evade immune recognition and destruction.
|
14612546 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H1 expression may thus significantly influence the outcome of T-cell tumor cell interactions and represents a novel mechanism by which glioma cells evade immune recognition and destruction.
|
14612546 |
2003 |
|
Malignant Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis of malignant glioma specimens revealed strong B7-H1 expression in all 10 samples examined, whereas no B7-H1 expression could be detected on normal brain tissues.
|
14612546 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection.
|
14686489 |
2003 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection.
|
14686489 |
2003 |
|
HIV Infections
|
0.070 |
Biomarker
|
group |
BEFREE |
Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection.
|
14686489 |
2003 |
|
Inflammatory Bowel Diseases
|
0.030 |
AlteredExpression
|
group |
LHGDN |
IECs from patients with IBD but not healthy controls expressed B7h and B7-H1 protein on their surface.
|
15131796 |
2004 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
|
15297412 |
2004 |
|
Multiple Sclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Here we characterize the expression and functional activity of B7-H1 expressed on monocytes and dendritic cells (DC) of healthy donors and MS patients.
|
15342209 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed in the DA1-3b/C3H mouse model of acute myeloid leukemia that dormant tumor cells resist cytotoxic T-lymphocyte (CTL)-mediated killing because they overexpress B7-H1.
|
15536145 |
2005 |
|
Esophageal Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery.
|
15837746 |
2005 |
|
Esophageal Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery.
|
15837746 |
2005 |
|
Esophageal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery.
|
15837746 |
2005 |
|
Malignant neoplasm of esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery.
|
15837746 |
2005 |